Adult asthmatics and acid reflux

Study identifier:SD-NEE-0003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, double-blind, parallel group multicenter efficacy and safety phase IIB pilot study of Esomeprazole 40mg bid versus placebo bid in adult asthmatics treated for 4 months

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

Study drug

Esomeprazole, Placebo

Sex

All

Actual Enrollment

1400

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Oct 2002

Primary Completion Date: 01 Apr 2004

Study Completion Date: 01 Apr 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	Drug: Esomeprazole 40mg twice a day Other Name: Nexium
Placebo Comparator: 2	Drug: Placebo 40mg twice a day

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1118&filename=CSR-SD-NEE-0003.pdf
Download
CSR-SD-NEE-0003.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Paula Fernstrom

Nexium Global Product Director, AstraZeneca